Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database

Fig. 2

Median survival outcomes (overall survival [OS], real-world progression-free-survival [rwPFS]) in metastatic breast cancer (mBC) patients after diagnosis of mBC, according to first-line treatment by tumor subtype (in months)

HR + , presence of hormone receptor; HR − , absence of hormone receptor; HER2 + , human epidermal growth factor receptor 2 (HER2) protein overexpression; HER2 − , no HER2 protein overexpression. CT, chemotherapy only; ET, endocrine therapy only; TT, targeted therapy only; CT& ET, chemotherapy and endocrine therapy; CT and TT, chemotherapy and targeted therapy; ET & TT, endocrine therapy and targeted therapy; CT, TT and ET, chemotherapy, targeted therapy and endocrine therapy. Median estimates are presented in months, with 95% confidence interval (95% CI)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us